CVRdatabase
Menu

SSI Diagnostica A/S

Public limited companyCVR 37294535HillerødActive

SSI Diagnostica A/S is a public limited company, based in Hillerød, active in manufacture of pharmaceutical preparations, founded in 2015. Measured by gross profit, it ranks no. 9 of 57 companies in the industry in the database. The company made a loss in both 2024 and 2025, most recently DKK 107.4m. With 151 employees, the company is about 15 times larger than the industry median.

Follow
PDF reportCompare

Key figures · financial year 2025

RevenueDKK 320.2m+34.4% vs. 2024
Net profit−DKK 107.4m−86% vs. 2024
EquityDKK 695.8m−45.2% vs. 2024
Employees151latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • Gross profit fell 9% (2024 → 2025), to DKK 110.5m.
  • Revenue rose 34% (2024 → 2025), to DKK 320.2m.
  • The loss grew: from DKK 57.7m to DKK 107.4m (2024 → 2025).
  • Equity fell 45% (2024 → 2025), to DKK 695.8m.

Employees

  • 10 more employees than a year earlier: 151 (07/2026) against 141 (07/2025).

Management and owners, last 24 months

  • New in management: Lars Henrik Vejrup Hansen (director, 01/01/2025) and Joseph Edward Bernardo (board member, 18/12/2025).
  • Stepped down: Stig Løkke Pedersen (board member, 18/12/2025) and Egil Mølsted Madsen (board member, 16/05/2025).

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 200mDKK 0DKK 200mDKK 400mDKK 600mDKK 800mDKK 1bnDKK 1.2bn202020212022202320242025
EquityNet profit
Financial figures for SSI Diagnostica A/S
202020212022202320242025Change
Revenuenot statednot stated316,074202,776238,338320,248+34.4%
Gross profit170,196274,461115,738107,395121,453110,465−9%
Operating profit (EBIT)95,986200,045−4,95224,88220,391−41,644−304.2%
Profit before tax99,625290,80426,461−108,116−61,601−118,800−92.9%
Net profit79,973251,42038,062−126,826−57,738−107,420−86%
Total assets843,307999,3223,185,3752,722,9332,672,9972,976,120+11.3%
Equity394,906690,0761,016,1461,247,7051,270,028695,791−45.2%
Liabilities426,609282,4092,154,0911,446,3991,374,1392,262,792+64.7%
Cash and cash equivalents24,05510,8039,83520,46413,98019,047+36.2%
Average number of employees112113125112121136+12.4%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

DKK 0DKK 50mDKK 100mDKK 150mDKK 200mDKK 250m202020212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Loss for 3 years in a row

    Net result has been negative in 2023–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

  • Equity fell sharply

    Equity fell 45% from 2024 to 2025 (DKK 1.3bn to DKK 695.8m).

    How is this calculated?

    Equity has fallen by at least 30% from the previous annual report, and it was positive the year before.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for SSI Diagnostica A/S
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202505/05/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202419/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202330/06/2024The companyPDFXBRL
202201/01/2022 – 31/12/202220/06/2023The companyPDFXBRL
202101/01/2021 – 31/12/202118/05/2022The companyPDFXBRL
202001/01/2020 – 31/12/202005/07/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
02040608010012014016008/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profitDKK 110.5mNo. 9 of 57
Better than 86% of the companies in the industry
EquityDKK 695.8mNo. 10 of 59
Better than 84% of the companies in the industry
Number of employees151No. 13 of 59
Better than 79% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bnHere
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 50–199 employees4,467 companies in the comparison
No. 541of 4,412
Better than 88%
No. 109of 4,466
Better than 98%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 287of 33,588
Better than 99%
No. 133of 33,687
Better than 100%
All companies of type A/S18,025 companies in the comparison
No. 1,426of 17,786
Better than 92%
No. 542of 18,024
Better than 97%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. SSI Diagnostica A/SDKK 110.5m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. SSI Diagnostica A/S−DKK 107.4m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. SSI Diagnostica A/SDKK 695.8m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. SSI Diagnostica A/S151
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
SSI Diagnostica A/S

Management

8 active registrations

Executive management

Executive management at SSI Diagnostica A/S
NameRoleAppointed
Christina Charlotte LindvedCEO24/02/2023
Lars Henrik Vejrup HansenDirector01/01/2025

Board of directors

Board of directors at SSI Diagnostica A/S
NameRoleAppointed
Rasmus Karl Gustaf MolanderBoard member30/09/2016
Patrik Olof DahlénBoard member15/09/2020
Sibel Karina ArnesBoard member18/08/2022
Ingo Sujit Michael ChakravartyBoard member16/08/2023
Nachum ShamirChair of the board16/08/2023
Joseph Edward BernardoBoard member18/12/2025
Founders
Statens Serum Institut
Former management (20)
Former management at SSI Diagnostica A/S
NameRoleAppointedResigned
Helle Birk KrogsgaardCEO11/12/201530/09/2016
Helle Birk KrogsgaardBoard member11/12/201530/09/2016
Nils Christian Strandberg PedersenChair of the board11/12/201507/09/2016
Mie Lund BuhlBoard member11/12/201530/09/2016
Ole JensenChair of the board13/09/201630/09/2016
Emil Staal BerganderDirector30/09/201631/10/2018
Steffen Kjeld ThomsenDirector30/09/201604/10/2016
Steffen Kjeld ThomsenBoard member30/09/201616/08/2023
Jan Gunnar ÅkessonChair of the board30/09/201604/10/2016
Stig Løkke PedersenChair of the board04/10/201615/08/2023
Patrik Olof DahlénDirector04/10/201616/09/2020
Bror Thomas PollareBoard member04/10/201612/08/2022
Sven Henrik Reinhold GeijerBoard member04/10/201631/08/2018
Christina Charlotte LindvedBoard member13/06/201824/02/2023
Catherine Yaping ChenBoard member15/09/202016/08/2023
Søren Skjold MogensenDirector16/09/202023/10/2023
Daniel Joseph DelaneyBoard member18/08/202228/02/2023
Egil Mølsted MadsenDirector24/02/202331/07/2024
Stig Løkke PedersenBoard member16/08/202318/12/2025
Egil Mølsted MadsenBoard member26/06/202416/05/2025

Signing rule: Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem og en direktør i forening eller af to direktører i forening.

Address and production units

2 active production units

Herredsvejen 2
3400 Hillerød

Hillerød Municipality · Postcode 3400

Other companies at the address (3)

Open in OpenStreetMap
Production units
Production unitAddressEmployeesP number
SSI Diagnostica A/SHerredsvejen 2, 3400 Hillerød1341020971777
SSI Diagnostica A/SFrederiksborgvej 71, 3450 Allerød161021739185

Purpose

Selskabets formål er at drive virksomhed med udvikling, produktion og salg af in vitro diagnostika til mikrobiologisk diagnostik og kontrol samt hygiejnemonitorering i indland og udland, samt anden dermed beslægtet virksomhed.

The purpose is quoted from the register in Danish.

Changes year by year

68 registered events
20261 changeaccounts 1
  • Annual report for 2025 published
20255 changesmanagement 4 · accounts 1
  • Joseph Edward Bernardo appointed board member
  • Stig Løkke Pedersen stepped down as board member
  • Annual report for 2024 published
  • Egil Mølsted Madsen stepped down as board member
  • Lars Henrik Vejrup Hansen appointed director
20244 changesmanagement 2 · accounts 1 · address 1
  • Egil Mølsted Madsen stepped down as director
  • Annual report for 2023 published
  • Egil Mølsted Madsen appointed board member
  • Moved to Herredsvejen 2, 3400 Hillerød
202314 changesaddress 1 · management 11 · accounts 1 · industry 1
  • Moved to Herredsvejen 2, 3400 Hillerød
  • Søren Skjold Mogensen stepped down as director
  • Ingo Sujit Michael Chakravarty appointed board member
  • Nachum Shamir appointed chair of the board
  • Stig Løkke Pedersen appointed board member
  • Catherine Yaping Chen stepped down as board member
  • Steffen Kjeld Thomsen stepped down as board member
  • Stig Løkke Pedersen stepped down as chair of the board
  • Annual report for 2022 published
  • Daniel Joseph Delaney stepped down as board member
  • Christina Charlotte Lindved appointed ceo
  • Egil Mølsted Madsen appointed director
  • Christina Charlotte Lindved stepped down as board member
  • Industry changed to Manufacture of pharmaceutical preparations (212000)
20225 changescapital 1 · management 3 · accounts 1
  • Share capital changed from 1,764,200 DKK to 1,765,000 DKK
  • Daniel Joseph Delaney appointed board member
  • Sibel Karina Arnes appointed board member
  • Bror Thomas Pollare stepped down as board member
  • Annual report for 2021 published
20211 changeaccounts 1
  • Annual report for 2020 published
20207 changescapital 2 · management 4 · merger 1
  • Share capital changed from 1,000,000 DKK to 1,764,200 DKK
  • Søren Skjold Mogensen appointed director
  • Patrik Olof Dahlén stepped down as director
  • Catherine Yaping Chen appointed board member
  • Patrik Olof Dahlén appointed board member
  • Share capital changed from 500,000 DKK to 1,000,000 DKK
  • Merger registered in CVR
20191 changeindustry 1
  • Industry changed to Manufacture of other chemical products n.e.c. (205900)
20183 changesmanagement 3
  • Emil Staal Bergander stepped down as director
  • Sven Henrik Reinhold Geijer stepped down as board member
  • Christina Charlotte Lindved appointed board member
201621 changesmanagement 17 · capital 1 · ownership 2 · industry 1
  • Bror Thomas Pollare appointed board member
  • Patrik Olof Dahlén appointed director
  • Stig Løkke Pedersen appointed chair of the board
  • Sven Henrik Reinhold Geijer appointed board member
  • Jan Gunnar Åkesson stepped down as chair of the board
  • Steffen Kjeld Thomsen stepped down as director
  • Share capital changed from 500,001 DKK to 500,000 DKK
  • Jan Gunnar Åkesson appointed chair of the board
  • Steffen Kjeld Thomsen appointed board member
  • Rasmus Karl Gustaf Molander appointed board member
  • Steffen Kjeld Thomsen appointed director
  • Emil Staal Bergander appointed director
  • Ole Jensen stepped down as chair of the board
  • Helle Birk Krogsgaard stepped down as ceo
  • Mie Lund Buhl stepped down as board member
  • Helle Birk Krogsgaard stepped down as board member
  • SSI Diagnostica Holding A/S registered as owner (100%)
  • Statens Serum Institut is no longer registered as owner
  • Ole Jensen appointed chair of the board
  • Nils Christian Strandberg Pedersen stepped down as chair of the board
  • Industry changed to Manufacture of basic pharmaceutical products (211000)
20156 changesfounded 1 · management 4 · ownership 1
  • Registered as SSI Diagnostica A/S
  • Helle Birk Krogsgaard appointed ceo
  • Mie Lund Buhl appointed board member
  • Helle Birk Krogsgaard appointed board member
  • Nils Christian Strandberg Pedersen appointed chair of the board
  • Statens Serum Institut registered as owner (100%)

Related companies

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 23/10/2026.

View in CVRReport a correction